Deltex Medical Group plc (DEMG:LSE) Annual Reports & Investor Relations Material

Overview

Deltex Medical has established itself as a top contender in the global haemodynamic monitoring technology industry. Its oesophageal Doppler monitoring (ODM) platform stands out for its ability to provide real-time and accurate information to anaesthetists, enabling them to administer fluids and drugs in surgical patients with greater precision. The company has an impressive track record, backed by solid clinical data, demonstrating that the ODM system helps clinicians achieve better surgical outcomes, reduce complications, and shorten patient hospital stays. Deltex Medical's latest study, FEDORA, showed significant reductions in overall complication risks and acute kidney injury, underscoring the potential of the company's innovative technology to revolutionize surgical and medical care.

Frequently Asked Questions

What is Deltex Medical Group plc's ticker?

Deltex Medical Group plc's ticker is DEMG

What exchange is Deltex Medical Group plc traded on?

The company's shares trade on the LSE stock exchange

Where are Deltex Medical Group plc's headquarters?

They are based in Chichester, England

How many employees does Deltex Medical Group plc have?

There are 11-50 employees working at Deltex Medical Group plc

What is Deltex Medical Group plc's website?

It is https://www.deltexmedical.com/

What type of sector is Deltex Medical Group plc?

Deltex Medical Group plc is in the Healthcare sector